ParkinsonFranceV1, PubMed, Corpus, bibRecord, 001539

Low-dose clozapine improves dyskinesias in Parkinson's disease.

Identifieur interne : 001539 ( PubMed/Corpus ); précédent : 001538; suivant : 001540

Low-dose clozapine improves dyskinesias in Parkinson's disease.

Auteurs : F. Durif ; M. Vidailhet ; F. Assal ; C. Roche ; A M Bonnet ; Y. Agid

Source :

Neurology [ 0028-3878 ] ; 1997.

RBID : pubmed:9065543

English descriptors

KwdEn :
- Aged, Antipsychotic Agents (administration & dosage), Clozapine (administration & dosage), Humans, Middle Aged, Movement Disorders (prevention & control), Parkinson Disease (drug therapy), Pilot Projects, Treatment Outcome.
MESH :
- chemical , administration & dosage : Antipsychotic Agents, Clozapine.
- drug therapy : Parkinson Disease.
- prevention & control : Movement Disorders.
- Aged, Humans, Middle Aged, Pilot Projects, Treatment Outcome.

Abstract

The severity of parkinsonian motor disability and dyskinesias was evaluated in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist apomorphine, before and after low-dose clozapine (50 mg) for 18 +/- 2 days. There was a significant 59% improvement (p < 0.05) of apomorphine-induced dyskinesias without aggravation of parkinsonian motor disability following clozapine treatment. The results suggest that low-dose clozapine, already shown to improve psychotic symptoms, may help to reduce severe levodopa-induced dyskinesias in parkinsonian patients.

PubMed: 9065543

Links to Exploration step

pubmed:9065543

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low-dose clozapine improves dyskinesias in Parkinson's disease.</title>
<author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name>
<affiliation><nlm:affiliation>Department of Neurology, Fontmaure Hospital, Clermont-Ferrand, INSERM U 289, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M" last="Vidailhet">M. Vidailhet</name>
</author>
<author><name sortKey="Assal, F" sort="Assal, F" uniqKey="Assal F" first="F" last="Assal">F. Assal</name>
</author>
<author><name sortKey="Roche, C" sort="Roche, C" uniqKey="Roche C" first="C" last="Roche">C. Roche</name>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1997">1997</date>
<idno type="RBID">pubmed:9065543</idno>
<idno type="pmid">9065543</idno>
<idno type="wicri:Area/PubMed/Corpus">001539</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001539</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Low-dose clozapine improves dyskinesias in Parkinson's disease.</title>
<author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name>
<affiliation><nlm:affiliation>Department of Neurology, Fontmaure Hospital, Clermont-Ferrand, INSERM U 289, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M" last="Vidailhet">M. Vidailhet</name>
</author>
<author><name sortKey="Assal, F" sort="Assal, F" uniqKey="Assal F" first="F" last="Assal">F. Assal</name>
</author>
<author><name sortKey="Roche, C" sort="Roche, C" uniqKey="Roche C" first="C" last="Roche">C. Roche</name>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name>
</author>
</analytic>
<series><title level="j">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1997" type="published">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antipsychotic Agents (administration & dosage)</term>
<term>Clozapine (administration & dosage)</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Movement Disorders (prevention & control)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Clozapine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severity of parkinsonian motor disability and dyskinesias was evaluated in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist apomorphine, before and after low-dose clozapine (50 mg) for 18 +/- 2 days. There was a significant 59% improvement (p < 0.05) of apomorphine-induced dyskinesias without aggravation of parkinsonian motor disability following clozapine treatment. The results suggest that low-dose clozapine, already shown to improve psychotic symptoms, may help to reduce severe levodopa-induced dyskinesias in parkinsonian patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9065543</PMID>
<DateCreated><Year>1997</Year>
<Month>03</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>1997</Year>
<Month>03</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN>
<JournalIssue CitedMedium="Print"><Volume>48</Volume>
<Issue>3</Issue>
<PubDate><Year>1997</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Neurology</Title>
<ISOAbbreviation>Neurology</ISOAbbreviation>
</Journal>
<ArticleTitle>Low-dose clozapine improves dyskinesias in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>658-62</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The severity of parkinsonian motor disability and dyskinesias was evaluated in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist apomorphine, before and after low-dose clozapine (50 mg) for 18 +/- 2 days. There was a significant 59% improvement (p < 0.05) of apomorphine-induced dyskinesias without aggravation of parkinsonian motor disability following clozapine treatment. The results suggest that low-dose clozapine, already shown to improve psychotic symptoms, may help to reduce severe levodopa-induced dyskinesias in parkinsonian patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durif</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Fontmaure Hospital, Clermont-Ferrand, INSERM U 289, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vidailhet</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Assal</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Roche</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bonnet</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Agid</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Neurology</MedlineTA>
<NlmUniqueID>0401060</NlmUniqueID>
<ISSNLinking>0028-3878</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber>
<NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year>
<Month>3</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1997</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1997</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">9065543</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001539 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001539 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:9065543
   |texte=   Low-dose clozapine improves dyskinesias in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:9065543" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Low-dose clozapine improves dyskinesias in Parkinson's disease.

Low-dose clozapine improves dyskinesias in Parkinson's disease.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki